Neurocognitive, psychiatric, and substance use characteristics in a diverse sample of persons with OUD who are starting methadone or buprenorphine/naloxone in opioid treatment programs.  Scott TM, Arnsten J, Olsen JP, Arias F, Cunningham CO, R…

Australien. Out-of-pocket costs for people receiving Opioid Agonist Treatment (OAT) equates to one-eight of their income new study shows Out-of-pocket costs associated with Opioid Agonist Treatment (OAT) equate to one-eighth of participants income…

Schweiz. Nationale Statistik der Substitutionsbehandlungen mit Opioid-Agonisten – Ergebnisse 2020. Labhart F., & Maffli E. (2021).  Lausanne: Sucht Schweiz. https://www.suchtschweiz.ch/fileadmin/user_upload/DocUpload/2021/Bericht-na…

Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report.  Joudrey PJ, Bart G, Brooner RK, Brown L, Di…

Barriers for Implementing the Hub and Spoke Model to Expand Medication for Opioid Use Disorder: A Case Study of Montana.  Green B, Rhubart DC, Filteau MR.  Subst Abuse. 2021 Aug 30;15:11782218211039781. doi: 10.1177/11782218211039781. PM…

Global patterns in opioid dependence and treatment: past history, current interventions, and future action (Video) Keynote speaker: Presidential Professor Emeritus, David T. Courtwright, author and historian on drug use. This session examined…